Nyxoah S.A - NYXH Business Value

Nyxoah S.A. (NYXH) develops Genio neurostimulators to combat apnea, where chip production becomes extremely low-cost following expensive trials. This chart illustrates the market price on GURU.Markets, which stands at 45.53, correlating with FDA approval expectations and expansion into Western countries. Despite a narrow development profile, Nyxoah S.A. (NYXH) relies on an innovative nerve stimulation method and the European market.

Enterprise Value sums market capitalization and net debt, determining the actual cost of a full business buyout accounting for all liabilities and liquidity. By analyzing the Enterprise Value structure on GURU.Markets, an investor sees the real scale of the asset, which is critical for Nyxoah S.A. (NYXH) during its preparation for the commercial launch of apnea treatment systems under the guidance of authoritative management.